Orum Taking Novel ADC Approach To Protein Degradation
New Funding To Advance Lead Candidates
Orum Therapeutics executives talk to Scrip on the next steps for the targeted protein degradation pioneer after a large-scale financing and on likely developments in the space in the coming years.
You may also be interested in...
Korean Bio/Healthcare Sector Sees Ample Fund Inflows In 2021
Financing for Korean bioventures and pharma firms remained strong this year amid ample liquidity and strong investor sentiment in the sector. SK Bioscience's IPO was the top fundraiser in 2021, followed by HK inno.N’s offering, while GI Innovation raised the most money from venture capital sources.
Scrip Asks…What Does 2021 Hold For Biopharma? Part 4: Technology And Disease
Around 100 executives highlight the hot areas to watch on the R&D front in 2021. From cancer to CNS and from regenerative medicine to real world data, expectations are high on many fronts.
Emocog Setting The Standard For Cognitive Decline DTx in Korea
In a little over two years, the Korean bio-digital healthcare platform company Emocog has moved its digital therapeutic for mild cognitive impairment into pivotal clinical trials and is discussing possible collaborations with big pharma firms, CEO Yoo Hun Noh tells Scrip.